全文获取类型
收费全文 | 408352篇 |
免费 | 27851篇 |
国内免费 | 4883篇 |
专业分类
耳鼻咽喉 | 5403篇 |
儿科学 | 8683篇 |
妇产科学 | 10430篇 |
基础医学 | 55519篇 |
口腔科学 | 12227篇 |
临床医学 | 34281篇 |
内科学 | 81751篇 |
皮肤病学 | 8795篇 |
神经病学 | 28207篇 |
特种医学 | 14899篇 |
外国民族医学 | 89篇 |
外科学 | 62834篇 |
综合类 | 17014篇 |
现状与发展 | 23篇 |
一般理论 | 64篇 |
预防医学 | 20279篇 |
眼科学 | 9997篇 |
药学 | 35035篇 |
45篇 | |
中国医学 | 4692篇 |
肿瘤学 | 30819篇 |
出版年
2021年 | 3904篇 |
2020年 | 2715篇 |
2019年 | 3527篇 |
2018年 | 5298篇 |
2017年 | 4399篇 |
2016年 | 4319篇 |
2015年 | 5377篇 |
2014年 | 7417篇 |
2013年 | 9243篇 |
2012年 | 12840篇 |
2011年 | 12975篇 |
2010年 | 8314篇 |
2009年 | 7636篇 |
2008年 | 11449篇 |
2007年 | 12319篇 |
2006年 | 12039篇 |
2005年 | 10887篇 |
2004年 | 9930篇 |
2003年 | 9648篇 |
2002年 | 9074篇 |
2001年 | 28915篇 |
2000年 | 29324篇 |
1999年 | 24029篇 |
1998年 | 5367篇 |
1997年 | 4436篇 |
1996年 | 3967篇 |
1995年 | 3611篇 |
1994年 | 3216篇 |
1993年 | 2902篇 |
1992年 | 16085篇 |
1991年 | 14845篇 |
1990年 | 14196篇 |
1989年 | 13983篇 |
1988年 | 12608篇 |
1987年 | 12081篇 |
1986年 | 11126篇 |
1985年 | 10332篇 |
1984年 | 6915篇 |
1983年 | 5600篇 |
1982年 | 2718篇 |
1979年 | 5480篇 |
1978年 | 3347篇 |
1977年 | 2971篇 |
1975年 | 2641篇 |
1974年 | 3064篇 |
1973年 | 2865篇 |
1972年 | 2828篇 |
1971年 | 2773篇 |
1970年 | 2511篇 |
1969年 | 2543篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
Tianying Yang Jiawei Li Yichen Jia Chunchen Yang Ruirui Sang Tongyu Zhu Ming Xu Ruiming Rong Cheng Yang 《Translational andrology and urology》2021,10(1):204
BackgroundIn the field of transplantation, inducing immune tolerance in recipients is of great importance. Blocking co-stimulatory molecule using anti-CD28 antibody could induce tolerance in a rat kidney transplantation model. Myeloid-derived suppressor cells (MDSCs) reveals strong immune suppressive abilities in kidney transplantation. Here we analyzed key genes of MDSCs leading to transplant tolerance in this model.MethodsMicroarray data of rat gene expression profiles under accession number in the Gene Expression Omnibus (GEO) database were analyzed. Running the LIMMA package in R language, the differentially expressed genes (DEGs) were found. Enrichment analysis of the DEGs was conducted in the Database for Annotation, Visualization and Integrated Discovery (DAVID) database to explore gene ontology (GO) annotation and their Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Their protein-protein interactions (PPIs) were provided by STRING database and was visualized in Cytoscape. Hub genes were carried out by CytoHubba.ResultsThree hundred and thirty-eight DEGs were exported, including 27 upregulated and 311 downregulated genes. The functions and KEGG pathways of the DEGs were assessed and the PPI network was constructed based on the string interactions of the DEGs. The network was visualized in Cytoscape; the entire PPI network consisted of 192 nodes and 469 edges. Zap70, Cdc42, Stat1, Stat4, Ccl5 and Cxcr3 were among the hub genes.ConclusionsThese key genes, corresponding proteins and their functions may provide valuable background for both basic and clinical research and could be the direction of future studies in immune tolerance, especially those examining immunocyte-induced tolerance. GSE28545相似文献
23.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
24.
A case of bullous pemphigoid associated with psoriasis vulgaris showing Hailey–Hailey disease‐like histopathological changes in regenerated epidermis without genomic mutation in ATP2C1 or ATP2A2 gene 下载免费PDF全文
25.
26.
27.
28.
29.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献